WeVote
Log In

Bill

Bill

HR 9559

IBOGAINE Act

119th Congress Introduced by Jack Bergman and 3 co-sponsors

The bill would accelerate development and access to psychedelic therapies for serious mental illness by streamlining research, regulatory approval, and patient access while strengt

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 9559

Summary of HR 9559 (Session 119)

Purpose and intent

  • HR 9559 aims to accelerate the development and access to psychedelic drugs that could save lives and address serious mental illness in the United States, including provisions to support research, development, and patient access.
  • The bill emphasizes reducing barriers to therapeutic use and increasing availability of psychedelic-based treatments as part of addressing mental health and related crises.

Key provisions and changes (proposed)

Note: The summary below reflects the intent based on the bill’s title and available action history. For precise text, please refer to the official bill language.

  • Research and development facilitation

    • Provisions intended to streamline and support federal research into psychedelic compounds (e.g., compounds with potential therapeutic benefits for mental health conditions).
    • Potential alignment with accelerated timelines for clinical trials and safety/efficacy evaluations.

  • Regulatory and approval pathways

    • Provisions to create or modify regulatory processes to expedite the development and review of psychedelic-based therapies while maintaining safety standards.
    • Possible collaboration between federal agencies to coordinate oversight, funding, and approvals.

  • Access and patient care

    • Measures aimed at increasing patient access to psychedelic-assisted therapies once approved, including potential funding, insurance coverage considerations, or distribution frameworks.
    • Emphasis on treatment for severe mental health conditions and crises where conventional treatments may be insufficient.

  • Education, training, and workforce

    • Investment in training healthcare professionals to administer and monitor psychedelic-assisted treatments.
    • Public health and clinician education components to ensure safe and appropriate use.

  • Safeguards and oversight

    • Provisions to preserve patient safety, informed consent, and monitoring of adverse effects.
    • Possible requirements for post-approval surveillance and data collection on outcomes.

Who would be affected

  • Patients with serious mental illnesses who may benefit from psychedelic-assisted therapies, including individuals experiencing crises related to mental health.
  • Researchers and academic medical centers conducting clinical trials and psychedelic research.
  • Healthcare providers and clinicians authorized to administer psychedelic-based treatments.
  • Federal agencies involved in regulation, funding, and oversight (e.g., health, justice, veterans’ affairs, and related committees as indicated by the action history).

Procedural and timeline aspects

  • Introduction: The bill was introduced in the House.
  • Referral: Referred to the House Committee on Energy and Commerce, with parallel referral to the Judiciary Committee and the Veterans’ Affairs Committee for provisions within their jurisdictions. The timeline for consideration remains to be determined by the Speaker.
  • Sponsors: Includes co-sponsors Michael McCaul, Jack Bergman, Morgan Luttrell, and Lou Correa, signaling bipartisan interest.

Potential implications

  • Accelerated development of psychedelic therapies could expand treatment options for patients with difficult-to-treat mental illnesses.
  • Regulatory and funding changes could influence how quickly new therapies move from research to clinical use.
  • Safeguards will be crucial to ensure patient safety, ethical conduct in research, and responsible use in clinical settings.

Note: For a precise, clause-by-clause understanding, including exact statutory language, definitions, funding mechanisms, and enforceable timelines, please consult the official bill text and legislative analyses from Congress.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.